Publications

Malabika Sen

Zhang L, Li Z, Liu Y, Xu S, Tandon M, Appelboom B, LaValle CR, Chiosea SI, Wang L, Sen M, Lui VWY, Grandis JR, Wang QJ. Analysis of oncogenic activities of protein kinase D1 in head and neck squamous cell carcinoma. BMC Cancer. 2018 Nov 12;18(1):1107. doi: 10.1186/s12885-018-4965-6. PubMed PMID: 30419840; PMCID: PMC6233608.
Bauman JE, Duvvuri U, Thomas S, Gooding WE, Clump DA, Karlovits B, Wehbe A, Miller FR, Kim S, Sen M, Heron DE, Grandis JR, Argiris A. Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives. Cancer. 2018 Oct 1;124(19):3881-3889. doi: 10.1002/cncr.31651. PubMed PMID: 30291796; PMCID: PMC6521720.
Johnston PA, Sen M, Hua Y, Camarco DP, Shun TY, Lazo JS, Grandis JR. High Content Imaging Assays for IL-6-Induced STAT3 Pathway Activation in Head and Neck Cancer Cell Lines. Methods Mol Biol. 2018;1683229-244. doi: 10.1007/978-1-4939-7357-6_14. PubMed PMID: 29082496; PMCID: PMC6507410.
Sen M, Johnston PA, Pollock NI, DeGrave K, Joyce SC, Freilino ML, Hua Y, Camarco DP, Close DA, Huryn DM, Wipf P, Grandis JR. Mechanism of action of selective inhibitors of IL-6 induced STAT3 pathway in head and neck cancer cell lines. J Chem Biol. 2017 Jul;10(3):129-141. doi: 10.1007/s12154-017-0169-9. PubMed PMID: 28684999; PMCID: PMC5480263.
Bauman JE, Duvvuri U, Gooding WE, Rath TJ, Gross ND, Song J, Jimeno A, Yarbrough WG, Johnson FM, Wang L, Chiosea S, Sen M, Kass J, Johnson JT, Ferris RL, Kim S, Hirsch FR, Ellison K, Flaherty JT, Mills GB, Grandis JR. Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. JCI Insight. 2017 Mar 23;2(6):e90449. doi: 10.1172/jci.insight.90449. PubMed PMID: 28352657; PMCID: PMC5358497.
Kiesel BF, Parise RA, Guo J, Huryn DM, Johnston PA, Colombo R, Sen M, Grandis JR, Beumer JH, Eiseman JL. Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation. Cancer Chemother Pharmacol. 2016 Dec;78(6):1225-1235. doi: 10.1007/s00280-016-3181-9. PubMed PMID: 27778071; PMCID: PMC5115981.
LaPorte MG, Wang Z, Colombo R, Garzan A, Peshkov VA, Liang M, Johnston PA, Schurdak ME, Sen M, Camarco DP, Hua Y, Pollock NI, Lazo JS, Grandis JR, Wipf P, Huryn DM. Optimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitors. Bioorg Med Chem Lett. 2016 Aug 1;26(15):3581-5. doi: 10.1016/j.bmcl.2016.06.017. PubMed PMID: 27381083; PMCID: PMC4964800.
Bauman JE, Zang Y, Sen M, Li C, Wang L, Egner PA, Fahey JW, Normolle DP, Grandis JR, Kensler TW, Johnson DE. Prevention of Carcinogen-Induced Oral Cancer by Sulforaphane. Cancer Prev Res (Phila). 2016 Jul;9(7):547-57. doi: 10.1158/1940-6207.CAPR-15-0290. PubMed PMID: 27339168; PMCID: PMC4930727.
Peyser ND, Wang L, Zeng Y, Acquafondata M, Freilino M, Li H, Sen M, Gooding WE, Satake M, Wang Z, Johnson DE, Grandis JR. STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma. Cancer Prev Res (Phila). 2016 Aug;9(8):657-63. doi: 10.1158/1940-6207.CAPR-16-0089. PubMed PMID: 27267892; PMCID: PMC4970880.
Kopechek JA, Carson AR, McTiernan CF, Chen X, Hasjim B, Lavery L, Sen M, Grandis JR, Villanueva FS. Ultrasound Targeted Microbubble Destruction-Mediated Delivery of a Transcription Factor Decoy Inhibits STAT3 Signaling and Tumor Growth. Theranostics. 2015;5(12):1378-87. doi: 10.7150/thno.12822. PubMed PMID: 26681983; PMCID: PMC4672019.
Johnston PA, Sen M, Hua Y, Camarco DP, Shun TY, Lazo JS, Wilson GM, Resnick LO, LaPorte MG, Wipf P, Huryn DM, Grandis JR. HCS campaign to identify selective inhibitors of IL-6-induced STAT3 pathway activation in head and neck cancer cell lines. Assay Drug Dev Technol. 2015 Sep;13(7):356-76. doi: 10.1089/adt.2015.663. PubMed PMID: 26317883; PMCID: PMC4556090.
Pollock NI, Wang L, Wallweber G, Gooding WE, Huang W, Chenna A, Winslow J, Sen M, DeGrave KA, Li H, Zeng Y, Grandis JR. Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies. Clin Cancer Res. 2015 Oct 15;21(20):4597-606. doi: 10.1158/1078-0432.CCR-14-3338. PubMed PMID: 26138066; PMCID: PMC4609280.
Sen M, Pollock NI, Black J, DeGrave KA, Wheeler S, Freilino ML, Joyce S, Lui VW, Zeng Y, Chiosea SI, Grandis JR. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth. Neoplasia. 2015 Mar;17(3):256-64. doi: 10.1016/j.neo.2015.01.003. PubMed PMID: 25810010; PMCID: PMC4372647.

<< Investigators Search

Top